Joint Venture Deals In Pharmaceuticals And Biotechnology 2016-2026 Now Available, Puts Actual SEC-Filed JV Contracts Behind 703 Companies Directly In Reach
Dublin, Sept. 03, 2026 (GLOBE NEWSWIRE) -- The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2026" report has been added to ResearchAndMarkets.com's offering.
The report covers strategic joint venture agreements announced in the pharmaceutical and biotechnology sector between 2016 and 2026, providing insights into deal structures, financial terms, and partnership strategies. A total number of deals was not provided in the source text.
Key Features & Benefits
- Comprehensive Coverage: Access a detailed compilation of joint venture deals, providing a broad perspective on industry trends.? In-Depth Deal Analysis: Examine the structures and financial terms of joint ventures, including ownership distributions, investment amounts, and governance arrangements.? Financial Benchmarking: Analyze disclosed financial terms to understand investment scales and expected returns, aiding in the assessment of fair market values.? Access to Actual Contract Documents: Benefit from direct links to online copies of actual joint venture contracts filed with the Securities Exchange Commission, offering unparalleled transparency into agreement specifics.? Identification of Active Dealmakers: Identify the top 25 companies most active in joint venture dealmaking, providing insights into potential partners and competitive strategies.?
What's Inside - Chapter Breakdown The report introduces the role and significance of joint ventures in the biopharma industry before examining dealmaking trends from 2016 to 2026, common deal structures, governance models, and financial arrangements. It also profiles leading joint venture agreements since 2016, identifies the top 25 most active dealmakers, and provides an extensive deal directory organized by company, therapy area, technology type, and industry sector, with links to contract documents where available.
Who Should Use This Report?
- Corporate Strategy & Business Development Teams: Evaluate joint venture models and identify optimal structures for risk-sharing and market expansion.? C-Level Executives & Investors: Assess strategic alignments and capital efficiencies in joint venture formations to inform investment decisions.? Legal & Transaction Advisors: Benchmark governance structures, equity distributions, and contractual terms to guide negotiations and ensure compliance.? Commercial Operations Teams: Understand how joint venture partners allocate commercialization responsibilities and regional market access.?
Why This Report Matters Joint ventures serve as a strategic intermediary between mergers & acquisitions and licensing agreements, combining financial alignment with collaborative innovation. As biopharma companies seek methods to mitigate development risks, expand geographically, or achieve commercial scale, joint ventures have emerged as a powerful mechanism for long-term value creation. This report elucidates the strategies and partnerships that have shaped successful joint ventures in the industry.?
Gain insights from real-world examples. Learn from industry leaders. Structure more effective partnerships.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in joint venture dealmaking
2.1. Introduction
2.2. Definition of joint venture deal
2.3. Trends in joint venture deals since 2016
2.3.1. Joint venture dealmaking by year, 2016-2026
2.3.2. Joint venture dealmaking by phase of development, 2016-2026
2.3.3. Joint venture dealmaking by industry sector, 2016-2026
2.3.4. Joint venture dealmaking by therapy area, 2016-2026
2.3.5. Joint venture dealmaking by technology type, 2016-2026
2.3.6. Joint venture dealmaking by most active company, 2016-2026
2.4. Reasons for entering into joint venture partnering deals
2.5. The future of joint venture deals
Chapter 3 - Overview of joint venture deal structure
3.1. Introduction
3.2. Joint venture agreement structure
Chapter 4 - Leading joint venture deals
4.1. Introduction
4.2. Top joint venture deals by value
Chapter 5 - Top 25 most active joint venture dealmakers
5.1. Introduction
5.2. Top 25 most active joint venture dealmakers
Chapter 6 - Joint venture deals including contracts directory
6.1. Introduction
6.2. Joint venture deals with contracts 2016-2026
Deal directory
Deal directory - joint venture dealmaking by companies A-Z
Deal directory - joint venture dealmaking by therapy area
Deal directory - joint venture dealmaking by technology type
Companies Featured
- 3SBio Accellix ADC Therapeutics AffyXell Therapeutics Aker BioMarine Alloy Therapeutics Amgen Apollo Therapeutics Arvinas AstraZeneca Atomwise Bayer BeiGene Bio-Techne BioNano Genomics Boehringer Ingelheim BridgeBio Pharma CRISPR Therapeutics Cyclica Daewoong Pharmaceutical Eli Lilly Evotec Exscientia Ferring Pharmaceuticals Ginkgo BioWorks GSK Heidelberg Pharma Horizon Discovery ImmunityBio Insilico Biotechnology Johnson & Johnson Kite Pharma Lonza Mayo Clinic Merck KGaA Novo Nordisk Oxford BioMedica Pfizer QIAGEN Roche Sanofi Seegene Takeda Pharmaceutical Tessa Therapeutics ThermoGenesis Verily Vivo Capital WuXi Biologics X-chem Zerion Pharma
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment